Literature DB >> 16530507

Decrease in mortality in Lynch syndrome families because of surveillance.

Andrea E de Jong1, Yvonne M C Hendriks, Jan H Kleibeuker, Sybrand Y de Boer, Annemieke Cats, Gerrit Griffioen, Fokko M Nagengast, Frits G Nelis, Matti A Rookus, Hans F A Vasen.   

Abstract

BACKGROUND & AIMS: Lynch syndrome family members have a high risk of developing colorectal (CRC), endometrial (EC), and other cancers. A large-scale surveillance program was introduced in The Netherlands in the late 1980s. The aims of the study were to evaluate the effectiveness of this program by assessing mortality because of CRC and EC before and after 1990 and to compare mortality because of all cancers (except CRC/EC) with mortality in the general population.
METHODS: Family members with at least 50% probability of being a carrier were selected for the study. The standardized mortality ratio (SMR) because of cancer and the absolute excess risk of death (AER) were calculated.
RESULTS: In the total cohort (N = 2788), 445 subjects had died because of cancer. The 3 most frequent causes of cancer-related deaths were CRC (50.3%), EC (6.7%), and brain tumors (6.7%). A significant decrease (70%) in SMR for CRC over time was observed (P < .001); the SMR for EC showed no decreasing trend over time. A significantly increased SMR was found for cancer of the small bowel (SMR = 18.3), brain (SMR = 9.1), kidney/ureter (SMR = 5.9), ovarium (SMR = 2.3), pancreas (SMR = 2.2), and stomach (SMR = 2.1). The AER was significantly increased for brain tumors only.
CONCLUSIONS: Since the introduction of surveillance, the mortality because of CRC has decreased. Except for brain tumors, we did not find a significantly increased AER for tumors other than CRC/EC.

Entities:  

Mesh:

Year:  2006        PMID: 16530507     DOI: 10.1053/j.gastro.2005.11.032

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  89 in total

1.  MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer.

Authors:  María Dolores Giráldez; Francesc Balaguer; Luis Bujanda; Miriam Cuatrecasas; Jenifer Muñoz; Virginia Alonso-Espinaco; Mikel Larzabal; Anna Petit; Victoria Gonzalo; Teresa Ocaña; Leticia Moreira; José María Enríquez-Navascués; C Richard Boland; Ajay Goel; Antoni Castells; Sergi Castellví-Bel
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.

Authors:  Fay Kastrinos; Ewout W Steyerberg; Rowena Mercado; Judith Balmaña; Spring Holter; Steven Gallinger; Kimberly D Siegmund; James M Church; Mark A Jenkins; Noralane M Lindor; Stephen N Thibodeau; Lynn Anne Burbidge; Richard J Wenstrup; Sapna Syngal
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

Review 3.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

4.  Public attitudes towards genomic risk profiling as a component of routine population screening.

Authors:  S G Nicholls; B J Wilson; S M Craigie; H Etchegary; D Castle; J C Carroll; B K Potter; L Lemyre; J Little
Journal:  Genome       Date:  2013-08-31       Impact factor: 2.166

5.  Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.

Authors:  Hanifa Bouzourene; Pierre Hutter; Lorena Losi; Patricia Martin; Jean Benhattar
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

6.  Screening colonoscopy intervals in familial colorectal cancer.

Authors:  Matthew F Kalady
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

Review 7.  Colorectal surveillance in Lynch syndrome families.

Authors:  Wouter H de Vos tot Nederveen Cappel; Heikki J Järvinen; Patrick M Lynch; Christoph Engel; Jukka-Pekka Mecklin; Hans F A Vasen
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 8.  Role of new endoscopic techniques in Lynch syndrome.

Authors:  Jasmijn F Haanstra; Jan H Kleibeuker; Jan J Koornstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 9.  Lynch syndrome: the patients' perspective.

Authors:  Jurgen Seppen; Linda Bruzzone
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

10.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.